Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of rHSA/EPO Fusion Protein in Healthy Subjects
NCT03786289Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recombinant human serum albumin/erythropoietin fusion protein in anemia (2 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Dec 2018; status: completed.
02
Drugs
recombinant human serum albumin/erythropoietin fusion protein
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03786289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786289.